Ehsan Sarafraz-Yazd, Ph.D., M.P.H.
Co-Founder & Chief Executive Officer
Josef Michl, M.D.
Co-Founder & Scientific Advisor
Kamyar Neshvadian, M.S., F.R.M.
Chief Financial Officer
Dr. Victor Adler, M.D., Ph.D.
Brad Evans, Ph.D.
Dallas Broadway, M.D.
Emil Lou, M.D., Ph.D.
Lisa Wisniewski, Ph.D.
As a cancer-geneticist and molecular biologist, Dr. Yazdi has 14 years of experience in the field of cancer. Prior to joining NomoCan, he was an Assistant Professor and translational research director at the Division of Gynecologic Oncology, State University of New York, Downstate Medical Center. He has several patents related to anti-cancer peptides which are at various stages of development by other companies. His research has been recognized by various awards including "Outstanding Clinical Scholar" award from the AACR/GlaxoSmithKline as well as by the Robert Furchgott Society (Nobel Prize in Medicine,’98). Dr. Yazdi received his Ph.D. in Cellular and Molecular Biology and M.P.H. in Health Policy and Management from SUNY Health Science Center- NY and his M.Sc. in Applied Genetics from University of Birmingham and Imperial College of London- U.K.
Dr. Michl is an expert in the field of cancer immunology and cell Biology. He has over 30 years of extensive training and research expertise in the areas of immunology and cancer, cell biology and immunotherapy. He is an inventor on several anticancer agents that are at various stages of development. Dr. Josef Michl is Associate Professor of Pathology, Cell and Molecular Biology, Microbiology and Immunology at SUNY Downstate Medical Center. He obtained his medical degree and training in Germany, Switzerland and at the Rockefeller University New York. Prior to joining SUNY Downstate Medical Center Dr. Michl has held academic positions at Universities in Switzerland, Germany and at The Rockefeller University New York, USA.
Mr. Neshvadian has over 8 years of experience in financial industry in various capacities. He was a member of portfolio management team of Global Macro strategy in Highbridge Capital Management (“HCM”), a subsidiary of JP Morgan Asset Management. Since 2014 he has joined Q-Squared Capital as the head of fixed income strategies. Mr. Neshvadian has developed, implemented and traded proprietary quantitative systematic strategies in all major asset classes, including fixed income, equities and commodities. Mr. Neshvadian has received an M.S. in Financial Engineering from New York University and an M.A. in statistics from Columbia University, where he was trained in machine learning algorithms for studying big data science, applicable to medicine.
Dr. Adler is a cancer molecular biologist with over 35 years of experience. He has extensive cancer research experience with over 300 peer-reviewed publications and various issued and pending patents. Prior to joining NomoCan, Dr. Adler has held multiple academic positions at various cancer centers including Mount Sinai, NY and University of Iowa Medical School. Dr. Adler received his MD, PhD from Second Moscow State Medical Institute, Russia.
Dr. Evans is a molecular biologist with over 19 years of cancer research experience. He has an extensive background in translational cancer research developing patient derived cellular models, biomarker discovery, and identification of novel therapeutic strategies for treatment of cancer. Prior to joining NomoCan, he held positions at Icahn school of Medicine at Mount Sinai, NYU School of Medicine and the Cancer Institute of New Jersey. Dr. Evans received his Ph.D. from Boston University.
Dr. Broadway is an interventional Radiologist by training. He is also trained in internal medicine. Dr. Broadway has over 15 years of experience in cancer research. He is an interventional Radiologist by training and is board certified in vascular and interventional radiology. He is also trained in internal medicine at State University of New York Health Science Center.
Dr. Emil Lou is a Medical Oncologist and physician-scientist in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota. His clinical specialties are gastrointestinal oncology and neuro-oncology. Dr. Lou has significant research experience within the field of oncology with more than 40 peer-reviewed publications. He is a diplomate of the American Board of Internal Medicine, and is board-certified in Medical Oncology, Internal Medicine, and Neuro-oncology. Dr. Lou received his M.D. and Ph.D. (Microbiology and Immunology) degrees from SUNY Upstate Medical University. He performed his residency training in Internal Medicine at Duke University Medical Center and then subsequently completed his Medical Oncology and Hematology fellowship at the Memorial Sloan-Kettering Cancer Center. He also completed an additional fellowship in Neuro-Oncology at the Preston Robert Tisch Brain Tumor Center at Duke University.
Dr. Wisniewski is a drug development executive with over 20 years of global experience driving the development and execution of pharmaceutical strategy. Dr. Wisniewski was Executive Director, Global Program Leader for Celgene from 2008 to 2012. Under her leadership, the business case and
global registration program for pomalidomide (Pomalyst
– with projected sales of over $1B in the next five years) were developed. Lisa led the plan up to successful NDA submission leading to approval in both the US and EU. Dr. Wisniewski received her BS from the University of Illinois and her MS and PhD from North Carolina State University, where she graduated Xi Sigma Pi and Sigma Xi, respectively. Following her PhD she completed a post-doc at Washington University in St. Louis.